NanoVation Therapeutics™ (NTx) is pleased to announce the expansion of its global gene therapy builder with the launch of its first GENErator™, NanoVationTx™ UK.

The operations of NTx UK will be tightly integrated with NTx Canada’s strategic direction. The extension of NTx Canada will bring decades of experience in creating nucleic acid therapeutics utilizing lipid nanoparticles to the UK whilst leveraging the UK’s outstanding environment for scientific innovation and collaboration.

The NTx UK technology hub will be based at the Harwell Science and Innovation Campus in Oxford. The team is led by Managing Director, Dr. Arpan Desai and Scientific Director, Dr. Frederick Campbell. This announcement comes in conjunction with the appointment of Professor Molly Stevens FRS FREng to the board of directors and global leadership team. The UK leadership team brings a wealth of commercial and academic expertise to the organisation.

NTx UK will be rapidly expanding the discovery research team with a focus on creating next-generation platform technologies for the safe and efficient delivery of nucleic acids to a variety of tissues. Concurrent with this effort, NTx will be establishing partnerships to explore new therapeutic applications.

“The addition of NanoVation Therapeutics UK is a critical strategic step in our growth as a leader in the lipid nanoparticle space. Our comprehensive and unencumbered IP portfolio for specialty lipids, LNP compositions as well as applications will be bolstered by the addition of our UK team.” says Dr. Dominik Witzigmann, Co-Founder and CEO of NanoVation Therapeutics.

“The gene therapy sector is rapidly growing in the UK, however delivery remains a critical bottleneck. Being part of the global NTx ecosystem, means NTx UK is ideally placed to generate the delivery science innovations that will enable the next wave of genetic medicines “ adds Dr. Arpan Desai, Managing Director of the NanoVation GENErator™ UK.

____________________________________________

NanoVation Therapeutics™ (NTx) is a privately held gene therapy company. Ntx is developing next-generation platform technologies utilizing lipid nanoparticles to enable nucleic acid delivery to a variety of tissues. Focused on translating personalized gene therapies to the clinic, NTx aims to treat and prevent multiple diseases enabling a healthier tomorrow, TODAY.

.